ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LID Lidco Group Plc

11.75
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lidco Group Plc LSE:LID London Ordinary Share GB0030546849 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.75 11.50 12.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Lidco Share Discussion Threads

Showing 6201 to 6222 of 7250 messages
Chat Pages: Latest  254  253  252  251  250  249  248  247  246  245  244  243  Older
DateSubjectAuthorDiscuss
10/4/2018
09:51
Some observations: with the LID share price at 6.5p Lidco is now a sitting duck for the receiving of a low ball offer of 10p a share

Lidco traded at over 10p around a year ago, sales are now set to improve as the final results outlook indicates
''The Board is targeting a year of significant sales growth for LiDCO products in 2018/19 compared with the year just ended and believes that gross profit margins will return to historical levels due to higher recurring revenues. Operational expenses are expected to remain at a similar level to 2017/18.

The Board believes that the Group has good prospects for growth and looks to the future with confidence.''

IMO a bid now of 10p would have to be referred to LID shareholders as it represents a premium of around 50% to the share price of LID today.

Re the ''results'' today I add some comments after , of my own musings.

1. China

''As previously announced, during the year, the Group made no sales to its Chinese distributor due to the requirement to gain further regulatory approval in China for a key accessory and the new monitor. LiDCO is continuing to support its distributor in seeking these regulatory approvals, and whilst it is difficult to forecast exactly when this will be achieved, the Group anticipates this will be during 2018. The future prospects for LiDCO in the country remain strong and we do not believe that this temporary delay in our sales effort will reduce our ability to take share in this rapidly developing hemodynamic market in the medium term.

Whilst the regulatory issue still needs resolving , and one would hope that what remains of 2018 should suffice, one would hope and expect that the current Chinese Distributor is building a back log of orders which can then be filled.
A resumption of sales to China should add IMO £1M plus in the first year it is resumed , perhaps the use of the HUP model might also be rolled out in China soon after.''


2. Lidco selling 3rd Party products in the UK

''Although notice has been given to terminate the distribution agreement for Argon Medical products at the end of September 2018, the Board aims to offset the effect of this by signing additional distribution agreements to take advantage of its sales reach in the UK.''

Argon was paying Lidco 20% for them to sell their products in the UK. This was a deal the new CEO was stuck with and has now ended.
20% is a very low percentage for a Distributor to agree to.
40% would be about the norm in the medical area from my research via other shares.

I expect Lidco as it is in a MUCH stronger position to bargain from.
Lidco is now the number one UK Hemodynamic monitor supplier to the NHS.
When the previous deal was struck with Argon it was not.

Thus Lidco should be able to strike a decent deal/s regarding the sale of 3rd party products into the NHS , using their position as a NHS approved supplier to do so.

I would expect 30% plus as the new percentage for Lidco to obtain for such an undertaking/s.


3. Japan

''Excluding China, sales in ROW actually grew by 52% driven by strong growth in Japan and the Middle East.



During the year, the Group announced the registration of its latest monitor platform and the appointment of Merit Medical Japan, a leading provider of critical care products, as its new exclusive distributor in Japan. Japan is the world's second largest market for advanced hemodynamic monitoring, it has a highly embedded market leader and is historically a conservative market to change. However, in the year, LiDCO experienced strong in-market growth of consumable sales and now, with the combined effects of launching our new monitor and partnering with Merit Medical, the Board believes that LiDCO is well positioned to gain greater market share in this important market.



Following good growth in the Middle East in the previous year, the Group decided to invest in a locally based clinical training resource. Working with our master distributor, we are building a good foundation across multiple countries and have been able to register our products in other key countries such as Saudi Arabia.

Sales to this country have been poor due to the previous deal signed with the previous distributor by the old CEO.

Things should now change for the better, Japan is now a growth area for Lidco and the HUP model may well once again be used for more established larger users of Hemodynamic monitoring.''


4. R.O.W

The new CEO has a wealth of Hemodynamic monitoring sales experience and was a previous Sales Director for a Lidco competitor.

He knows that the signing of a well worded deal with the 'right' distributor is key to sales growth for the company. I expect he will use his previous sales experience to Lidco's advantage,lucky for Lidco shareholders then.


From the results today this outlook statement seems quite confident ... however will it now attract a bid from a larger predator that Lidco has already won work from in the USA ? wild card would be a Chinese company.





''Outlook

The Board is targeting a year of significant sales growth for LiDCO products in 2018/19 compared with the year just ended and believes that gross profit margins will return to historical levels due to higher recurring revenues. Operational expenses are expected to remain at a similar level to 2017/18.



The Board believes that the Group has good prospects for growth and looks to the future with confidence.''

buywell3
10/4/2018
06:48
Trading update disappointing...market will be brutal I think.

Expect this to go down 3-4p on the cards unfortunately.

multibagger
10/4/2018
06:31
Oh dear me, what a terrible set of results, available cash down a whopping 33.3%, only 2 years cash left before a placing, HUP hasn't done much for the bottom line, so much for MSs magic touch.
gbenson1
09/4/2018
15:33
Happy Annual Increment, except that it's negative, oh dear.
arf dysg
29/3/2018
19:07
Hello All Idiots
maxk
29/3/2018
19:02
Here Am I?
arf dysg
28/3/2018
08:32
Hieroglyphics Anonymous Inscriptions?
arf dysg
27/3/2018
17:56
Does HAI stand for:

Holy Anointed Igloo?
Hopeless And Ignorant?
Hairy Animal Inundation?
Helpless Apoplectic Itch?
Horrible Appalling Injury?
Hilariously Atrocious Idiocy?
Hurtling Astronomically Into-the-heart-of-the-sun?

arf dysg
26/3/2018
09:20
buywell, please tell us what HAI is.
arf dysg
25/3/2018
17:59
Lidco is the number one supplier of Hemodynamic Monitoring equipment to the UK NHS.



Interim Results for the six months ended 31 July 2017
10 Oct 2017 07:00:02


Sales Performance

In the UK, where the Company enjoys over 50% market share, its market leading position was strengthened with LiDCO product revenues up 14% to £2.0m.

The first half performance was boosted by strong capital revenues, with the new LiDCOunity v2 monitor generating revenues of £0.3m in July, the first month of its commercial release.

Feedback on the new monitor has been very positive and a number of monitor orders were received via the new sales channel opened during 2016 when LiDCO products were awarded a NHS Supply Chain Framework Agreement.

Recurring revenues declined 4% to £1.6m due to the timing of customer orders and does not reflect a weakening in the underlying business.

The Company expects a stronger second half with full year recurring revenues growing over the prior period as LiDCO continues to gain market share.


This UK growth has continued

Lidco sees total revenues rising in 2018
15th February 2018


In the UK, Lidco had another strong performance, building on its market leading position as product revenues are expected to be up 9% to £4.14m (2017: £3.79m). The growth was driven by strong monitor sales.


Today we read that Mrs May is to pump an extra £4 Billion into the NHS and more operations should result.

With extra cash coming in , the growth of Lidco Hemodynamic Monitoring sales into the UK NHS looks set to not only continue but increase due to more operations being carried out.


News today in the Sunday Times

May orders £4 Billion Brexit boost to save ailing NHS






New LiDCOunity v2 monitor launch
Published on Tuesday, May 9th, 2017
9 May 2017

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has been granted a CE mark for its latest product, the LiDCOunity v2 and will showcase it in Europe at the 5th ERAS World Congress, which will be held in Lyon, France from 10-12 May 2017.

Enhanced Recovery After Surgery (“ERAS”) is a well-established multimodal, evidence-based, perioperative care pathway designed to improve recovery after surgery. LiDCO technology has been used in published clinical research as a key component of ERAS care pathways. The ERAS World Congress is organised by The ERAS Society, a not for profit academic society working to implement best practice in surgical care worldwide.

Built on a striking new slim widescreen monitor platform the LiDCOunity v2 incorporates the core value proposition of combining the full suite of LiDCO technology into one offering.

Bringing together LiDCO’s non-invasive, minimally invasive and calibrated technologies it allows continuous hemodynamic monitoring, including monitoring of level of consciousness across the entire clinical pathway in one monitor. In addition it has a number of new additional features, such as an updated graphical user interface with a more intuitive menu system, internal battery for transportation and new clinical guidance protocols to aid users.

More information about LiDCOunity V2 can be found on our new website www.lidco.com




IMO non-invasive Hemodynamic Monitors will become the norm over time due to HAI

dyor

buywell3
22/3/2018
12:23
...and while we're at it, the LiDco share price is higher than it was a year ago, a fact which should please you immensely.
arf dysg
22/3/2018
12:22
buywell3 (5403) "None invasive Hemodynamic monitoring"

FFS! You can't even tell the difference between the words "none" and "non" !!!


For your information, it's "non-invasive" ....NOT "none invasive".



Exactly which part of LiDco's product range is non invasive?

Pulmonary-artery catheters are highly invasive.


So please tell us which of LiDco's products is/are non invasive?

arf dysg
22/3/2018
07:36
After due deliberation and further reflection

Non-invasive Hemodynamic monitoring is where the future growth lies IMO

As risks associated with invasive hemodynamic monitoring, such as sepsis, bleeding, hemorrhage, thrombosis, air embolism, and pulmonary capillary necrosis, are challenging the growth of the hemodynamic monitoring systems market.

I put these risks under the heading HAI ... Hospital Acquired Infections
In 2014, results of a project known as the HAI Prevalence Survey were published. The Survey described the burden of HAIs in U.S. hospitals, and reported that, in 2011, there were an estimated 722,000 HAIs in U.S. acute care hospitals (see chart below). Additionally, about 75,000 patients with HAIs died during their hospitalizations. More than half of all HAIs occurred outside of the intensive care unit.


This could explain why some competitors of Lidco are now losing market share to them, ie if their product is more invasive, as well as not so accurate or so quick at detecting a problem with the patient



Work is being done to reduce HAI , but it will IMO always remain an problem area


Re some recent Lidco news and comments


The link below is worth visiting to listen to what the Lidco CEO says about very recent developments





The recent USA HUP win in California he refers to to in the above, was from Edwards Lifesciences

Edwards Lifesciences have around a 70% market share in the USA of the Hemodynamic monitoring market and are a Global World leader in that market.

The Hemodynamic Monitoring Systems Market worth is expected to be worth

1,143.7 Million USD by 2021



That Lidco have now got a USA hospital in California to switch to them from Edwards Lifesciences must have come as a bit of a shock to Edwards , as California is where their HQ is located, ie their own home turf.

Locations - Edwards Lifesciences

Global Locations. Our corporate headquarters are located in Irvine, California, and we supply products and technologies to clinicians in nearly 100 countries around the world.


If as I suspect , Lidco now get other USA Hospitals to switch to their new monitors , away from Edwards Lifesciences , by choosing the HUP option.

Lidco will begin to become more than just a thorn in Edwards Lifesciences side.

One can also assume Lidco are also targeting USA wins by use of their HUP offering to gain market share from other competitors.


New LiDCOunity v2 monitor launch
Published on Tuesday, May 9th, 2017
9 May 2017

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has been granted a CE mark for its latest product, the LiDCOunity v2 and will showcase it in Europe at the 5th ERAS World Congress, which will be held in Lyon, France from 10-12 May 2017.

Enhanced Recovery After Surgery (“ERAS”) is a well-established multimodal, evidence-based, perioperative care pathway designed to improve recovery after surgery. LiDCO technology has been used in published clinical research as a key component of ERAS care pathways. The ERAS World Congress is organised by The ERAS Society, a not for profit academic society working to implement best practice in surgical care worldwide.

Built on a striking new slim widescreen monitor platform the LiDCOunity v2 incorporates the core value proposition of combining the full suite of LiDCO technology into one offering.

Bringing together LiDCO’s non-invasive, minimally invasive and calibrated technologies it allows continuous hemodynamic monitoring, including monitoring of level of consciousness across the entire clinical pathway in one monitor. In addition it has a number of new additional features, such as an updated graphical user interface with a more intuitive menu system, internal battery for transportation and new clinical guidance protocols to aid users.

More information about LiDCOunity V2 can be found on our new website www.lidco.com




IMO non-invasive Hemodynamic Monitors will become the norm over time due to HAI

dyor

buywell3
15/3/2018
14:02
TEB, why don't we give him the old good cop, bad cop routine?

You wade in there and tell him what a big mistake he's making, then I'll come in and tell him that he's a good investor really, and it could be so much easier if he'd just buy steadily and slowly. Then we each invent three new avatars which can criticise each other until Nobbygnome bans us all.

arf dysg
13/3/2018
20:42
Gspanner falling into the same trap as many before him.Can nobody save him?
trentendboy
11/3/2018
08:01
I think the entire Deltex bulletin board were beamed up - it can be the only explanation.

I suspect they think that alien invaders are the only chance of actually selling any probes at good margins.

trentendboy
08/3/2018
08:16
That is a lot of years of hurt
trentendboy
07/3/2018
21:45
I see The Count is still trumpeting about the technology but failing to judge the marketplace as always. 17 years of b------t.
Probes far too costly in a financially handcuffed market.

willib2
01/3/2018
17:22
Lest we forget:

The share price is higher than it was a year ago!

arf dysg
25/2/2018
19:26
buywell3 (5392)

"Good to see LiDCO expanding its Distributions network
North Korea next perhaps ?"


That's what you meant, isn't it?

The LiDCo rapid will be even more rapid than before, with the ability to launch a monitor into inter-continental ballistic flight and deliver an exciting package to anywhere in the United States.

arf dysg
22/2/2018
13:22
Good to see LiDCO expanding its Distributions network

South Korea next perhaps ?


LiDCO Group Plc Appointment of French distributor



22 February 2018



Appointment of French distributor

LiDCO (AIM: LID), the hemodynamic monitoring company, announces that it has signed an exclusive three year agreement with Spacelabs Healthcare SAS France to distribute LiDCO products in France. Spacelabs Healthcare SAS France is part of Spacelabs Healthcare which itself is a wholly owned subsidiary of OSI Systems (NASDAQ/OSIS).

Spacelabs Healthcare designs and manufactures advanced patient monitoring devices, anesthesia delivery and ventilation systems, diagnostic cardiology devices, software, and supplies and accessories. It employs more than 1,100 people around the world.

France is currently the fifth largest medical device market in the world, with an established adoption of hemodynamic monitoring. LiDCO's technology has never been actively promoted in France and the Board believes that there are opportunities with its minimally invasive and non-invasive technologies, in the hands of the right strategic partner, to gain share in this large market.

More information about LiDCO can be found on the Company's website www.lidco.com

Commenting on the distribution agreement, Matt Sassone, Chief Executive Officer of LiDCO, said:

"This is an exciting development for our business in Europe. We are looking forward to working with Spacelabs to launch our latest monitor. It's important that we have partnered with such a credible company with an established brand and infrastructure in France, as we look to penetrate this large market."






N+1 Singer Reiterates “Buy” Rating for LiDCO Group (LID)
The Lincolnian Online-Feb 19, 2018

LiDCO Group plc logo N+1 Singer reiterated their buy rating on shares of LiDCO Group (LON:LID) in a report released on Friday morning. They currently have a GBX 14 ($0.19) price objective on the stock.

Separately, FinnCap reiterated a corporate rating and set a GBX 14 ($0.19) price target

buywell3
16/2/2018
09:51
3rd-party sales are 16.9% of total.


And lest we forget:

The share price is higher than it was a year ago!

arf dysg
Chat Pages: Latest  254  253  252  251  250  249  248  247  246  245  244  243  Older

Your Recent History

Delayed Upgrade Clock